Capricor Therapeutics, Inc. Q3 2025 Earnings Preview

* Capricor Therapeutics, Inc. (CAPR [https://seekingalpha.com/symbol/CAPR]) is scheduled to announce Q3 earnings results on Monday, November 10th, after market close.
* The consensus EPS Estimate is -$0.54 [https://seekingalpha.com/symbol/CAPR/earnings/estimates] and the consensus Revenue Estimate is $0.48M (-79.1% Y/Y).
* Over the last 1 year, CAPR has beaten EPS estimates [https://seekingalpha.com/symbol/CAPR/earnings/eps-surprise-summary] 100% of the time and has beaten revenue estimates 100% of the time.
* Over the last 3 months, EPS estimates have seen 0 upward revisions [https://seekingalpha.com/symbol/CAPR/earnings/revisions] and 5 downward. Revenue estimates have seen 0 upward revisions and 2 downward.

MORE ON CAPRICOR THERAPEUTICS, INC.

* Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026 [https://seekingalpha.com/article/4826709-capricor-post-crl-path-to-dmd-cardiomyopathy-approval-in-2026]
* Capricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory Pathway [https://seekingalpha.com/article/4826578-capricor-therapeutics-stock-buy-ahead-phase-3-topline-clarified-regulatory-pathway]
* Capricor Therapeutics, Inc. (CAPR) DMD Program Update Call (Transcript) [https://seekingalpha.com/article/4825911-capricor-therapeutics-inc-capr-dmd-program-update-call-transcript]
* Capricor gains as FDA mulls ‘regulatory flexibility’ for lead asset [https://seekingalpha.com/news/4498923-capricor-gains-fda-mulls-flexibility-lead-asset]
* Capricor Therapeutics, Inc. Q2 2025 Earnings Preview [https://seekingalpha.com/news/4484295-capricor-therapeutics-inc-q2-2025-earnings-preview]